Ondine Biomedical Inc.
OBIMF
$0.11
-$0.02-15.39%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 313.90K | 318.60K | 284.80K | 288.90K | 159.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 313.90K | 318.60K | 284.80K | 288.90K | 159.30K |
| Cost of Revenue | 120.60K | 122.40K | 118.70K | 120.40K | 65.90K |
| Gross Profit | 193.30K | 196.20K | 166.10K | 168.50K | 93.40K |
| SG&A Expenses | 1.75M | 1.77M | 1.47M | 1.49M | 2.16M |
| Depreciation & Amortization | 99.40K | 100.90K | 101.40K | 102.90K | 109.40K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.18M | 3.22M | 2.77M | 2.81M | 3.15M |
| Operating Income | -2.86M | -2.90M | -2.49M | -2.53M | -2.99M |
| Income Before Tax | -2.84M | -2.88M | -2.39M | -2.43M | -2.94M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.84M | -2.88M | -2.39M | -2.43M | -2.94M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.84M | -2.88M | -2.39M | -2.43M | -2.94M |
| EBIT | -2.86M | -2.90M | -2.49M | -2.53M | -2.99M |
| EBITDA | -2.83M | -2.87M | -2.46M | -2.49M | -2.94M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 241.47M | 241.47M | 226.75M | 226.75M | 194.72M |
| Average Diluted Shares Outstanding | 241.47M | 241.47M | 226.75M | 226.75M | 194.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
